A roundtable consensus meeting was held to consolidate current knowledge on the etiology of colorectal cancer in patients with inflammatory bowel disease and to review current strategies, both diagnostic and preventive, specifically addressing the role of 5‐aminosalicylic acid. Specific topics that were addressed included: the epidemiology of colorectal cancer, including an assessment of risk factors and the impact of colonoscopy on colorectal cancer incidence and mortality; the origin and evolution of dysplasia nomenclature and the natural history of dysplasia; review of the experience of St. Mark's Hospital (London) as gleaned from its surveillance database; mechanisms by which 5‐aminosalicylic acid is thought to exert a chemopreventive effect; the potential future role of 5‐aminosalicylic acid in chemopreventive strategies; chemoprevention in familial adenomatous polyposis; and other future research directions. This article provides a comprehensive overview of the issues discussed and should act as a guide to shaping the design of future studies in this area.
1University of Chicago Medical Center, Chicago, Illinois
2University of Puerto Rico Comprehensive Cancer Center, San Juan, Puerto Rico
3Medical University of Vienna, Vienna, Austria
4St. Mark's Hospital, Harrow, United Kingdom
5University of Pennsylvania, Philadelphia, Pennsylvania
6Johns Hopkins University School of Medicine, Baltimore, Maryland
7Mount Sinai Hospital, Toronto, Ontario, Canada
8University Hospital of North Tees, Stockton on Tees, United Kingdom
9Mount Sinai School of Medicine, New York, New York
10University of California, San Francisco, California
*From the Section of Gastroenterology, Hepatology, and Nutrition, Department of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, MC 4076, Chicago, IL 60637
Received 31 August 2007; Accepted 4 September 2007
Published online 11 October 2007 in Wiley Online Library (wileyonlinelibrary.com).
Grant sponsor: Shire Pharmaceuticals Inc., Wayne, Pennsylvania.